出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2014/05/16 21:20:51」(JST)
Combination of | |
---|---|
Olanzapine | Atypical antipsychotic |
Fluoxetine | SSRI |
Clinical data | |
Trade names | Cinol Forte, Cinol Plus, Depten-OZ, M-Olan Plus, Oladay-F, Olanex-F, Olapin Forte, Olapin Plus, Olorest-F, Symbyax |
AHFS/Drugs.com | entry |
Pregnancy cat. | C (AU) C (US) |
Legal status | ℞-only (US) not controlled |
Routes | Oral |
Identifiers | |
ATC code | N06CA03 |
Y (what is this?) (verify) |
The drug combination olanzapine/fluoxetine (trade name Symbyax, created by Eli Lilly and Company) is a single capsule containing the atypical antipsychotic olanzapine and the selective serotonin reuptake inhibitor (SSRI) fluoxetine. Olanzapine/fluoxetine is primarily used to treat the depressive episodes of bipolar I disorder as well as treatment-resistant depression.[1]
Olanzapine/fluoxetine was approved by the U.S. Food and Drug Administration (FDA) to treat the depressive episodes of bipolar I disorder in 2003.[1] In 2009, it was granted approval for the treatment of treatment-resistant depression.[2]
Olanzapine/fluoxetine, or other antidepressant/antipsychotic combinations, are sometimes prescribed off-label for anxiety disorders,[3] eating disorders,[4] obsessive–compulsive disorder (OCD),[5] and posttraumatic stress disorder (PTSD).[6]
Olanzapine/fluoxetine is available as a capsule. Currently, five dosage combinations are produced (measured in mg olanzapine/mg fluoxetine): 3 mg/25 mg, 6 mg/25 mg, 6 mg/50 mg, 12 mg/25 mg, 12 mg/50 mg.[1]
Possible side effects of olanzapine/fluoxetine include all those of the two component drugs: olanzapine and fluoxetine. Common side effects include suicidal thoughts, increased appetite, weight gain, drowsiness, fatigue, dry mouth, swelling, tremor, blurred vision and difficulty concentrating.[1]
Olanzapine/fluoxetine could produce a severe allergic reaction and should not be used if the patient has previously experienced an allergic reaction to either fluoxetine or olanzapine.[7]
Olanzapine, is correlated with an increase in blood sugar. Patients with diabetes, or those at risk for developing it, require careful monitoring.[7]
In rare cases, olanzapine/fluoxetine may cause neuroleptic malignant syndrome.[1]
Like other SSRIs, olanzapine/fluoxetine carries a black box warning stating that it could increase the risk of suicide in patients ages 24 and under. The warning also states that olanzapine/fluoxetine may increase the risk of death in elderly patients with dementia-related psychosis.[1]
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
リンク元 | 「SYMBYAX」 |
.